Hypercalcemia during pregnancy: management and outcomes for mother and child by Appelman-Dijkstra, N.M. (Natasha) et al.
Endocrine
https://doi.org/10.1007/s12020-021-02615-2
CLINICAL MANAGEMENT OF ENDOCRINE DISEASES
Hypercalcemia during pregnancy: management and outcomes for
mother and child
Natasha M. Appelman-Dijkstra 1 ● Diana- Alexandra Ertl2,3 ● M. Carola Zillikens4 ● Lars Rjenmark5 ●
Elizabeth M. Winter1
Received: 24 November 2020 / Accepted: 8 January 2021
© The Author(s) 2021
Abstract
Diagnosing and treating hypercalcemia during pregnancy can be challenging due to both the physiological changes in
calcium homeostasis and the underlying cause for the hypercalcemia. During pregnancy and lactation there is increased
mobilization of calcium in the mother to meet the fetus’ calcium requirements. Here we discuss the diagnostic challenges,
management, and patient perspective of hypercalcemia during pregnancy in two particular cases and in other rare conditions
causing hypercalcemia.
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Introduction
Hypercalcemia in pregnancy is rare and in >90% of cases
caused by a newly diagnosed primary hyperparathyroidism
(PHPT). Hypercalcemia during pregnancy due to other
disorders of calcium metabolism is even more rare and lit-
erature regarding the maternal management and fetal out-
comes is lacking. Diagnosing hypercalcemia is challenging
during pregnancy, as symptoms such as fatigue or nausea
mimic those in early pregnancy. However, longstanding
hypercalcemia might induce nephrolithiasis, pancreatitis,
and preeclampsia in the mother [1]. Therefore, the occur-
rence of these diseases during pregnancy should push the
physicians to screen for hypercalcemia. In the fetus,
maternal hypercalcemia can result in fetal growth restriction
[2]. Following birth, further complications may arise such
as severe neonatal hypocalcemia, tetany, and even death
due to fetal hypoparathyroidism [3, 4]. In rare calcium-
related disorders, the diagnosis is often known before
the pregnancy and patients and partners can be counseled by
the treating endocrinologist, obstetrician, pediatrician, and
geneticist when required, taking into account the possible
physical and mental maternal adverse effects, but also the
eventual consequences for the newborn. Here we would like
to discuss the diagnostic challenges and management of
hypercalcemia during pregnancy in two particular cases as
example of rare conditions causing hypercalcemia compli-
cating pregnancy.
Case 1
A 34-year-old woman was referred with severe hypercal-
cemia and a pregnancy wish. At the age of 24 she was
diagnosed with PHPT, without underlying genetic causes.
During parathyroidectomy (PTX) there was spill of the
adenoma, histologically confirmed, which led to chronic
hypercalcemia for which she underwent several re-
operations in various hospitals including a thyroidectomy
in 2 tempi with resection of surrounding fat-tissue and a
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bilateral modified lymph node resection. However, she
remained dependent on cinacalcet and bisphosphonates in
various dosages. At referral, albumin-corrected serum cal-
cium was 2.89 mmol/L (ref 2.15–2.55 mmol/L) with PTH
10.7 (ref 1–8 pmol/L) while on cinacalcet 60 mg/day, and
3.16 mmol/L with PTH of 29 without cinacalcet. She and
her partner were counselled by a team consisting of gyne-
cologists, pediatricians, and endocrinologists on several
aspects of the disease and potential consequences for a
pregnancy. Prophylactic surgery was not possible at that
time. Bisphosphonates were stopped and she became
pregnant after 12 months. Cinacalcet was stopped and a
fluid intake of 4 L was advised. However, she was admitted
with a symptomatic hypercalcemia, 3.4 mmol/L, within
2 weeks. Hyperhydration and cinacalcet, up to 90 mg/day,
were started in combination with furosemide 40 mg and
acetylsalicylic acid 80 mg daily as preeclampsia prophy-
laxis. She suffered from severe hyperemesis gravidarum and
due to persistent hypercalcemia, she received saline infu-
sions of 5 L/day in a homecare setting with a peripheral
intravasal central catheter (PICC). During follow up the
PICC caused deep vein thrombosis for which nadroparin
injections were started but with this treatment serum cal-
cium remained stable around 2.7–2.9 mmol/L. At 38 weeks
of gestation she developed hypertension with a rapidly
developing HELLP syndrome and an emergency cesarean
section was performed. A healthy baby boy, weight 3305 g,
was delivered; he only received active vitamin D supple-
mentation for a few days and two years after delivery; no
calcium disturbances or skeletal abnormalities have been
observed. The mother did not breastfeed. After delivery,
the mother experienced a post-traumatic stress syndrome
(PTSS) with depression for which she started Eye Move-
ment Desensitization and Reprocessing (EMDR). The
depression and PTSS was related to the latter part of the
pregnancy and delivery, but most likely exacerbated due to
a postpartum rise in calcium to 3.3 mmol/L. Surgery was
successfully performed after which her mental complaints
improved.
Case 2
A 38-year-old female was diagnosed with PHPT at a non-
university hospital, based on a modest hypercalcemia, and
elevated PTH of 9.2 pmol/L and high to normal urinary
calcium excretion of 8.5 g/L and calcium-to-creatinine
clearance above 0.02. Despite her young age, it was deci-
ded not to perform PTX because of an increased risk for
venous thromboembolism and obesity. Five years later, she
had an unexpected pregnancy and was referred for PTX in
the second trimester. During that time serum calcium had
increased from 2.63 mmol/L to 2.83 mmol/L with a non-
suppressed PTH of 3.8 pmol/L. The patient and her partner
were counseled by a team consisting of endocrinologists,
anesthesiologists, endocrine surgeons, pediatricians, and
obstetricians. Imaging studies did not reveal a clear-cut
adenoma and considering the progressive rise in calcium to
2.93 mmol/L, urinary calcium excretion of 12 g/L in 24 h
and proceeding into the end of the second trimester an
elective neck exploration was performed at gestational age
of 24+ 2 weeks, showing four gland hyperplasia. During
surgery, it was decided to remove only the two right-sided
glands in order not to risk hypoparathyroidism. After sur-
gery hypercalcemia persisted with calcium levels between
2.60 mmol/L and 2.65 mmol/L and PTH between 2.1 pmol/
L and 3.6 pmol/L. Considering the marked hyperplasia the
patient was discussed in the clinical patient management
system (CPMS) panel of main thematic group two, calcium
and phosphate disorders of the European Reference Net-
work for rare endocrine diseases (ENDO-ERN). The advice
of this panel was to perform genetic testing for familial
hypocalciuric calciuria (FHH), which came back positive
for a mutation in the CASR-gen, c.653A>G p.(Tyr218Cys),
establishing a diagnosis of FHH type one. At 39+ 3 weeks
she delivered a healthy baby girl of 4150 g without any
calcium disturbances. Post-partum the calcium levels of the
mother remained at 2.6 mmol and PTH rose again to
10.3 pmol/L, which has been stable since.
Patient perspective
Patient one had an active pregnancy wish for 5 years, with a
negative counselling in several centers. At the Leiden
University Medical Center (LUMC) it was again made clear
that this would not be without risks for mother and child but
if desired we would do our best to monitor the pregnancy as
good as possible, which was much appreciated as this was
not discussed before. Although she was well prepared and
extensively counseled, the intensity of the pregnancy was
overwhelming. Both the high calcium levels, frequent
investigations and the continuous hyperhydration were
extremely demanding and resulted, together with the further
rise in calcium, in a pre- and post-natal depression for which
EMDR and psychotherapy were needed. Looking back, she
would advise other patients to realize that it will be extre-
mely tough, but absolutely worth it. The fact that caretakers
were so involved in her well-being and their clear com-
munication was helpful and appreciated. The health care
system structure with various doctors during hospital
admission remains unfortunate from her point of view,
which was in contrast to the outpatient clinic care with one
regular healthcare provider.
Despite living with, a supposed, PHPT for many years,
patient 2 had never been counseled about PHPT in terms of
treatment and follow up. In the initial phase of her referral
to LUMC this was done rapidly as time was ticking for a
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safe window of surgery as the second trimester is the pre-
ferred trimester for surgery for maternal and fetal reasons.
In addition, due to her increased risk for venous throm-
boembolism and obesity, emergency surgery in case of
severe hypercalcemia was considered to be a high risk for
the mother. The patient found the amount of information
overwhelming. However, it was appreciated as it made the
patient and her partner feel part of the team. After surgery,
when she had postoperative pains, this induced more stress
being pregnant. Caregivers should be aware that in pregnant
patients’ complaints that might be considered as normal
after surgery can induce a stressful trigger in patients who
are already in a stressful situation. The doubts about the
original diagnosis of PHPT were shared including the desire
of the treating physicians to discuss her case with other
experts. Although providing more insecurity, the patient did
feel comfortable that this meant that no other surgery was
likely to be needed. After the pregnancy she reported that
the physical part of the pregnancy did not give her many
discomforts but the uncertainty about the well-being of the
baby was very stressful. But overall, she was very satisfied
with the care given.
In collaboration with these patients we produced a
checklist for women in the same position or with a recent
diagnosis of PHPT, which might be of help, see Table 1.
In both cases patients and partners experienced the
pregnancy as a rollercoaster with lot of uncertainties.
Whereas both patients were diagnosed with hypercalcemia
before pregnancy, patient 1 was counseled extensively in
the pre-pregnancy period and even repeatedly got the advice
not to become pregnant while patient 2 was never coun-
seled. Also, in patient 2 the diagnosis was changed from
PHPT to FHH, the finding of the marked hyperplasia trig-
gered doubts about the original diagnosis of PHPT. In
patient 1, the initial decision for surgery would still be made
as her calcium values were rising and she did develop
nausea and in FHH hyperplasia is also often described.
Physiological changes during pregnancy (Fig. 1a)
During pregnancy and lactation there is increased mobili-
zation of calcium in the mother to meet the fetus’ calcium
requirements [5, 6]. This is done by increasing intestinal
calcium absorption through increasing 1.25 vitamin D
production and PTH-related peptide (PTHrP), which is
released from placenta and breasts in response to estradiol,
placental lactogen, and prolactin [6, 7]. Despite the over-
lapping modes of action, PTH and PTHrP are produced by
different genes on different chromosomes and the gene
encoding PTHrP is more complex than for PTH. PTHrP is
undetectable in the circulating blood of non-pregnant
women, but is produced in a paracrine/autocrine fashion
during pregnancy. Lessons from PTHrP or PTH1R gene
knockout mice, which die at birth or in utero, emphasize the
critical role of PTHrP for normal life [8, 9]. In addition,
nascent PTHrP isoforms are processed by members of the
prohormone convertase family to at least three fragments:
N-terminal PTHrP [1–36], structurally related to PTH; a
mid-region PTHrP (38–94); and a C-terminal PTHrP
(107–139) with distinct biological properties and receptors.
PTHrP is able to act not only via the classical autocrine/
paracrine pathways, but also through a so-called intracrine
pathway, which involves the translocation of the protein
into the nucleus, where it can directly regulate proliferation
and apoptosis [10, 11]. PTHrP has multiple activities
including control of fetal development, trans-epithelial
calcium transfer, lactation, smooth muscle relaxation, and
cell growth. The mid-molecular region of PTHrP stimulates
placental calcium transport in the fetus, while the COOH
terminal region may also affect osteoclast activity.
Thus, although PTHrP was discovered as a tumor-derived
hypercalcemic factor, its primary physiological role is as a
local regulator of many physiological processes especially
in early life [12, 13].
Maternal causes and consequences of hypercalcemia
(Fig. 1b)
Hypercalcemia due to hyperparathyroidism is the most
described cause of hypercalcemia during pregnancy. As most
Table 1 Questions for women in the childbearing age to ask their
doctor when diagnosed with a high calcium level
1. What is the most likely diagnosis causing this high
calcium level?
2. What tests do I need to make the diagnosis more likely? And are
these tests influenced by pregnancy?
3. How will this affect pregnancy?
What will be the risks for my unborn child?
What will be the risks for me?
Which interventions are possible/necessary before, during and
after pregnancy?
4. What can I do to minimalize complaints during and after the
pregnancy?
5. How can we decrease my risk for preeclampsia?
6. Which drugs might be used during the pregnancy and what are
their side effects?
7. How can you monitor my child?
8. How will my disease affect me after delivery?
9. How will this affect my child directly after delivery?
10. Can I breastfeed?
11. Who is in my multidisciplinary team and how can I reach them?
12. What can be done by my general practitioner?
13. What would be the risk of getting pregnant and to whom can I
speak to for counseling?
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reviews focus on maternal and fetal outcomes in PHPT we
will not cover this topic in the current paper [14, 15].
Hyperparathyroidism due to diffusely spread hyperthyroid
nodules, parathyromatosis, post-parathyroidectomy, in the
context of malignancy, MEN syndromes, or in chronic renal
disease has been rarely described [15, 16]. Literature data on
parathyromatosis is limited to around 20 cases published so
far with only one report on a woman diagnosed and treated
during pregnancy [17, 18].
FHH is a rare autosomal dominant disorder, with a pre-
valence of ~1:78.000 though this might likely be higher, as
many cases remain asymptomatic lifelong and no causal
treatment is available [19–21]. According to the genetic
defect causing the pathology, three types of FHH have been
defined [21–24]. FHH1 is the most common type and is
found in about 65% of all FHH cases [21]. Patients with
FHH present with mild to moderate hypercalcaemia, low
urinary excretion, and PTH serum levels that are either
normal or slightly elevated. Many patients with FHH are
misdiagnosed as suffering from PHPT as in the case of our
patient. Data on FHH manifested during pregnancy, litera-
ture data are sparse. Only four cases were published so far.
Fig. 1 a *Intravascular fluid expansion causes gestational hypoalbu-
minemia. The dilutional hypoalbuminemia of pregnancy leads to a
decline in total calcium concentration. Ionized calcium on the other
hand, remains stable and may provide more accurate information.
** The increase in 1.25 vitamin D production leads to an increase in
intestinal calcium absorption. ***“Absorptive hypercalciuria of preg-
nancy”. Postprandial and 24-h urinary calcium excretion increase after
12 weeks, due to increased intestinal calcium absorption supposedly
unrelated to increased formation of 1.25 vitamin D in early pregnancy.
Fasting urine samples will not be affected by this phenomenon [45].
b *Prednison to reduce 1.25OH formation and thus intestinal calcium
absorption. ** Reducing PTH-rp production mammae. *** No clinical
data during pregnancy, only case reports. In animal studies no
abnormalities observed, but it does pass the placenta [31, 46].
Breastfeeding: in animal studies (rat), cinacalcet is found in milk [46].
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Walker et al. reported the case of a pregnant patient, initially
diagnosed with PHPT, who showed no improvement after
PTX. The newborn presented with asymptomatic hyper-
calcemia; the genetic analysis confirmed the diagnosis of
FHH [25]. The newborn presented elevated serum calcium
levels with no clinical symptoms, while the genetic analysis
confirmed the diagnosis of FHH. Others reported hyper-
calcemic profiles for which they underwent surgery during
pregnancy [26, 27].
PTHrP-induced hypercalcemia during pregnancy or lac-
tation has also been reported, either with or without
gigantomastia [28–33]. In the reported cases, associating
gigantomastia and increased PTHrP serum values, hyper-
calcaemia was diagnosed during gestation and resolved
only after mastectomy, bromocriptin administration, or
termination of pregnancy [29, 31, 32].
After delivery, there is a risk of severe hypercalcemia in
women with PHPT who are lactating as PTH-rp production
will increase [6, 34]. Especially women with gestational
hypercalcemia with gigantomastia should be advised
against breastfeeding as this will keep PTHrp levels high.
The rise in PTHrp during pregnancy was not seen in patient
1 in whom PTHrp production was fully suppressed during
entire pregnancy. The observed rise in calcium levels in
patient 2 might in retrospect be due to her different setpoint
and PTHrp production. Mental consequences of hypercal-
cemia are well known and include depression and anxiety
[35, 36]. During pregnancy mothers might have additional
stress which might be exaggerated by the hypercalcemia.
Fetal consequences of hypercalcemia
In the fetus, maternal PHPT can result in fetal growth
restriction, severe neonatal hypocalcemia, tetany, and
death [36]. In maternal FHH potential fetal complications
include mild hypercalcemia, severe hypocalcemia, or neo-
natal severe hyperparathyroidism, depending on the geno-
type of the fetus. Because FHH is an autosomal dominant
condition, three genetic situations might be encountered by
the newborns of FHH mothers: the unaffected and the
heterozygous neonates might present with hypocalcaemia
induced by the in utero suppression of the parathyroid, the
latter being at risk of developing hypercalcemia with
hypocalcaemia in the first year of life. The homozygous
form of FHH results in a severe neonatal hyperparathyr-
oidism, which requires the surgical removal of the glands
during the neonatal phase [37, 38].
Most outcomes on the fetal consequences of hypercal-
cemia were described in reports on patients with PHPT.
Untreated hypercalcemia was associated with fetal or neo-
natal complications in the majority of cases [3, 36, 39, 40].
However, these findings are based on early literature of
PHPT patients when hypercalcemia was often diagnosed in
an advanced stage and more recent literature has shown
that, compared to age-matched controls, women with PHPT
had no difference in most pregnancy outcomes, including
stillbirths [39]. That same study also showed that Apgar
scores and anthropometric measurements were similar to
babies born in uncomplicated pregnancies. However, this
recent study did not report on maternal outcomes of pre-
eclampsia. Other recent studies also report lower compli-
cations rates and good treatment outcomes when the
hypercalcemia is moderate and not severe [1, 41].
Elevated maternal serum calcium leads to hypercalcemia
in the fetus, which causes fetal parathyroid gland suppres-
sion. After delivery, these glands are still suppressed
causing fetal hypocalcemia, which is usually transient
(lasting 3–5 months after birth), but permanent hypopar-
athyroidism has anecdotally been described [42].
In the case of parathyromatosis diagnosed during preg-
nancy, Edling et al. reported that the infant presented
initially with high calcium and low PTH levels, which
normalized rapidly, with no further complications [18].
Newborns of mothers presenting with humoral hypercal-
cemia of pregnancy were having normal calcium levels at
birth [29, 30, 33].
Diagnosing hypercalcemia during pregnancy might be
challenging due to both physiological changes in calcium
homeostasis, as well as due to the underlying cause for
the hypercalcemia; changes in urinary calcium excretion
vary during daytime, introducing difficulty in using urin-
ary calcium indices as a diagnostic tool. In non-pregnant
population, the measurement of calcium/creatinine clear-
ance ratio can be useful in distinguishing between PHPT
(>0.02 mmol/mmol) and FHH(<0.01 mmol/mmol). How-
ever, it is known that almost 20% of FHH patients might
present with a calcium/creatinine ratio >0.01, and indivi-
duals with PPHT and simultaneous vitamin D deficiency
might show lower than expected calcium excretion [43].
Genetic testing, when available, should be considered for
confirming the clinical suspicion of FHH. More than 130
CaSR mutations have been reported so far in relation to
FHH1, fact that explains the phenotypical variations in
relation to the observed differences in serum calcium and
PTH levels [21, 44].
During pregnancy, the distinction between FHH and
PHPT is further complicated by the physiological changes
in maternal calcium metabolism: increased breast and pla-
cental production of PTHrP, that together with the placental
lactogen, leads to an increase in 1,25-(OH)2- vitamin D and
a reduction of the PTH levels. As a result, the intestinal
calcium absorption and the urine calcium excretion are
physiologically increased [5, 45]. Treatment is depending
on the underlying cause and might be invasive or con-
servative, but all decisions need good counseling, as it
concerns not only the mother, but also the fetus and partner
Endocrine
as well. Also we, as physicians, need to be aware that the
treatment does not stop with the deliverance of a healthy
baby and that the postpartum period might actually be the
period with the highest risk for the mother due to the risk of
sudden rises in calcium level and to excessive mental stress
caused by possible events during pregnancy or delivery.
But foremost, irrespective of the underlying cause of
hypercalcemia, patients and partners need to be closely
involved in the decision processes in order to ensure overall
good outcomes for mother and child.
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